AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00956306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: 100mg Single Oral Dose of Udenafil
Study NCT02862249 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation
Description: The FMT (200mls) will be administered following preparation of the bowel with MoviPrep®, into the duodenum via a gastroscope derived from 50g of fresh donated stool from a healthy donor. The gastroscopy will be performed as per the King's College Hospital Gastroenterology Protocol.
Study NCT02862249 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An identical appearing placebo solution (200mls 0.9% normal saline and 12.5% glycerol) will be administered into the duodenum via a gastroscope in a single blinded fashion following preparation of the bowel with MoviPrep®.
Study NCT02506218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 + 20 g protein consumption
Description: whey isolate
Study NCT02506218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 30 g protein breakfast
Description: 30 g mixed meal breakfast
Study NCT02506218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10 g protein breakfast
Description: 10 g mixed meal breakfast
Study NCT03578848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home BP
Description: As for the home BP measurements, a validated device (WatchBP Home; Microlife AG, Widnau, Switzerland) will be provided for all subjects allocated to the home BP arm to measure their BP at home. Subjects are requested to take BP in the morning (within 2 hours after awakening) and afternoon before meals for 7 consecutive days before the scheduled clinical visits. BP in the first day of the measurements will be discarded and an average of home BP (all BP reading and BP in the morning and in the afternoon) will be generated and provided for clinicians to guide their treatment.
Study NCT02541084 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Anti-VEGF therapy following the Summary of Product Characteristics
Study NCT03312335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Aldesleukin (Proleukin®)
Description: Subcutaneous injection of 1.5 million international units (MIU) of Aldesleukin (Proleukin®, Interleukin-2) once daily in 5-day courses every three weeks for a total of 4 cycles.
Study NCT02371421 — intervention group
Intervention type: DRUG
Intervention: Allopurinol
Study NCT03321526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive JNJ-42847922 capsule orally.
Study NCT03321526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matching to JNJ-42847922
Description: Participants will receive placebo capsule matching to JNJ-42847922 orally.
Study NCT03321526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine XR
Description: Participants will receive quetiapine XR capsule orally.
Study NCT03321526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Matching to Quetiapine XR
Description: Participants will receive placebo capsule matching to quetiapine XR orally.
Study NCT03321526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI)
Description: Participants will receive SSRI antidepressant (such as, citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, vilazodone or vortioxetine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
Study NCT03321526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI)
Description: Participants will receive SSRI antidepressant (such as, citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, vilazodone or vortioxetine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
Study NCT03321526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Description: Participants will receive SNRI antidepressant (such as duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
Study NCT03321526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Description: Participants will receive SNRI antidepressant (such as duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
Study NCT03115606 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-Mac D Blade
Description: Videolaryngoscope
Study NCT03115606 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fastrach LMA
Description: Laryngeal mask airway
Study NCT01687452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Study NCT01687452 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood samples
Study NCT00612586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzastaurin
Description: 1125 milligram (mg) loading dose, then 250 mg twice daily, oral up to 1 year (yr) or until progressive disease
Study NCT00612586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, daily (up to 1 yr or until progressive disease)
Study NCT00612586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (LV)
Description: 400 milligram per meter squared (mg/m\^2) intravenously (IV), Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
Study NCT00612586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leucovorin (LV)
Description: 400 milligram per meter squared (mg/m\^2) intravenously (IV), Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
Study NCT00612586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Description: 400 mg/m\^2 bolus then 2400 mg/m\^2 IV over 46 hours, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
Study NCT00612586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-fluorouracil (5-FU)
Description: 400 mg/m\^2 bolus then 2400 mg/m\^2 IV over 46 hours, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
Study NCT00612586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Bev)
Description: 5 milligram per kilogram (mg/kg) IV, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
Study NCT00612586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab (Bev)
Description: 5 milligram per kilogram (mg/kg) IV, Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
Study NCT03922867 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: A web-based educational platform to deliver cognitive behavioral therapy (CBT) for insomnia
Study NCT02613364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Undergo yoga intervention
Study NCT02613364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Intervention
Description: Undergo CBT-I intervention
Study NCT02613364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive health education
Study NCT02613364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02613364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02613364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Correlative studies
Study NCT02613364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring Device
Description: Correlative studies
Study NCT02613364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02613364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03557658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexagliflozin
Description: Single oral dose of bexagliflozin tablet, 20 mg
Study NCT01667354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic Detailing
Description: The intervention design is based on academic detailing, an effective method of changing physician behavior. The aim of the training is effective communication with parents who are hesitant about childhood vaccinations.
Study NCT04946045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor Interventions (Tactile/Kinesthetic Stimulation+Nonnutritive Sucking)
Description: Sensorimotor interventions were applied to in preterm infants between 30-33 weeks of age for 10 days. After that, preterms were included in the Six-phase feeding progression protocol.
Study NCT03330314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12460A
Description: HM12460A is a long-acting insulin
Study NCT04201470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood withdrawal
Description: Measurement of serum neurofilaments light chain and GFAP
Study NCT04201470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood withdrawal
Description: Measurement of serum neurofilaments light chain and GFAP
Study NCT04201470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Cervical and cerebral MRI without contrast injection
Study NCT04201470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Cervical and cerebral MRI without contrast injection
Study NCT04201470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurologic / neuropsychologic tests - Patients
Description: EDSS (Expanded Disability Status Scale), NHPT (Nine Hole Peg Test), T25FW (Timed 25-Foot Walk Test), 6MWT (Six-Minute Walk Test), CSCT (Computerized version of the Symbol Digit Modalities Test)
Study NCT04201470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurologic / neuropsychologic tests - Controls
Description: NHPT, T25FW, CSCT
Study NCT00467831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan potassium tablet, 25 mg by mouth every night at bedtime.
Study NCT00467831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zileuton
Description: Zileuton tablet, 1200 mg by mouth twice daily.
Study NCT00467831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-acetylcysteine solution, 600 mg by mouth three times daily.
Study NCT00467831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pravastatin sodium tablet, 20 mg by mouth every night at bedtime.
Study NCT00467831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Erythromycin tablet, 333 mg by mouth three times daily.
Study NCT02860819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Veliparib 250mg BID, continuously
Study NCT02860819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 800mg/m2, day 1 and 8
Study NCT02860819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC = 4, day 1
Study NCT00928226 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiosurgery (SRS)
Description: Standard of care
Study NCT03578848 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home BP
Description: As for the home BP measurements, a validated device (WatchBP Home; Microlife AG, Widnau, Switzerland) will be provided for all subjects allocated to the home BP arm to measure their BP at home. Subjects are requested to take BP in the morning (within 2 hours after awakening) and afternoon before meals for 7 consecutive days before the scheduled clinical visits. BP in the first day of the measurements will be discarded and an average of home BP (all BP reading and BP in the morning and in the afternoon) will be generated and provided for clinicians to guide their treatment.
Study NCT03578848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBP
Description: For the uAOBP and CBP, the measurements will be conducted in a quiet room without the presence of clinical personnel. Patients will be seated in a quiet room without talking and taken as an average of 3 measurements with an automated device (HEM-907, Omron Healthcare, Lake Forest, IL) that has been preset to wait 5 minutes before measurements. Simultaneously, the central BP will be measured in the other upper arm. (WatchBP Office Central; Microlife AG, Widnau, Switzerland). The determination of the right or left upper arm for uAOBP or central BP will be made in a random order by computer generated random codes before the enrollment.
Study NCT02976376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Box
Description: The Box contains four smartphone compatible devices. Patients will measure their vital signs and automatically send them to the hospital.
Study NCT04279379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg d1,ivdrip, repeated every 3 weeks
Study NCT04279379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 10mg d1-5, ivdrip,repeated every 3 weeks
Study NCT01218412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Motivational Interviewing
Description: Participants will engage in 4 sessions of web-based motivational interviewing over the course of 4 weeks.
Study NCT01117688 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscopy with and without safety guidewire
Description: In study arm A - with SGW, endoscopic treatment is performed with a safety guidewire in place. In study arm B - without SGW, the ureteroscopy is performed without SGW.
Study NCT00958308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BIO-K+ CL-1285®
Description: A mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
Study NCT00958308 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: BIO-K+ CL-1285®
Description: A mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
Study NCT01992354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET MR Device
Description: GE PET/MRI system
Study NCT00958308 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo is devoid of microorganisms.
Study NCT00958308 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is devoid of microorganisms.
Study NCT01762657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Cyclosporine and Oral Lansoprazole
Description: Oral Cyclosporine A dosed at 7.5 mg/kg/day and Oral Lansoprazole dosed at 30 mg in two divided dosages to subjects ages 8-15 and 60 60 mg in divided dosages to subjects ages 16-60. The Cyclosporine A and Lansoprazole may be given as an oral tablet/capsule or oral suspension.
Study NCT01762657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Two oral placebos are given at breakfast and dinner. The placebos may be given as an oral tablets/capsules or oral suspensions.
Study NCT05374616 — intervention group
Intervention type: GENETIC
Intervention: Observation
Description: Retrospective and prospective Natural History Study
Study NCT04269954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batroxobin combined with low molecular weight heparin
Description: Standard treatment of Batroxobin combined with low molecular weight heparin
Study NCT04269954 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Batroxobin combined with low molecular weight heparin
Description: Standard treatment of Batroxobin combined with low molecular weight heparin
Study NCT04806152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: Supervised high-intensity combined-modality exercise was administered to participants in the exercise arm for 3 times per week for 6 months. A post-exercise recovery protein drink (31g whey-based) was given within 15 minutes after each supervised exercise session.
Study NCT04806152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care home exercise
Description: Walking 30 minutes, chair rises and flexibility exercises for trunk and upper extremities 5 days per week
Study NCT02347410 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SIFS graft containment device
Description: The SIFS mesh is a graft containment and reinforcement device. Following conventional thorough discectomy, the disc space is entered through a small portal in the annulus, the SIFS mesh is introduced, deployed and then filled with bone graft. Bilateral commercially available posterior lumbar fixation is applied.
Study NCT02525198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fatty acid/flavonoid blend
Description: see arm description
Study NCT02525198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: see arm description
Study NCT00702052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus tablets
Study NCT03003780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Steps
Description: Integrated website, activity tracker, and mind-body training
Study NCT01266655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Baclofen will be administered orally for a maximum of 20 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams t.i.d.; subsequently, the daily dose of baclofen will be increased to a maximum of 90 milligrams t.i.d. within 4 weeks. In case of intolerance, dosage can be decreased to a minimum of 10 mg t.i.d.. Patients will receive maximum tolerated dosage of baclofen for 12 weeks. Medication will then gradually be tapered over a maximum of 4 weeks.
Study NCT00928226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Standard of care
Study NCT00455962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol steroid infusion
Description: Estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr
Study NCT00455962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone steroid infusion
Description: Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr
Study NCT00097786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg + nateglinide 60 mg
Description: The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
Study NCT00097786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg + nateglinide placebo
Description: The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.